News - Latuda, Sunovion

Filter

Current filters:

LatudaSunovion

Popular Filters

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

09-11-2013

The US Food and Drug Administration on Friday approved Sunovion Pharmaceutical’s (a subsidiary of Japanese…

AptiomDainippon Sumitomo PharmaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Dainippon Sumitomo sets up subsidiary in Singapore

21-01-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) has established a wholly-owned subsidiary in…

Asia-PacificDainippon Sumitomo PharmaMarkets & MarketingPharmaceuticalSunovion

Sunovion files two sNDAs for Latuda with FDA

09-09-2012

Sunovion Pharmaceuticals, a US subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506) has submitted…

Dainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Sunovion to acquire Elevation Pharma for up to $430 million

03-09-2012

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506) last week…

Dainippon Sumitomo PharmaElevation PharmaceuticalsEP-101Mergers & AcquisitionsPharmaceuticalRespiratory and PulmonarySunovion

Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression

09-05-2012

Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) Co., Ltd. (DSP) announced has results from two…

Dainippon Sumitomo PharmaLatudaNeurologicalPharmaceuticalResearch

Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients

30-10-2011

Sunovion Pharmaceuticals (SEPR: US) has announced results from a 12-month, double-blind extension study…

AstraZenecaLatudaNeurologicalPharmaceuticalResearchSeroquel XRSunovion

FDA accepts ciclesonide NDA from Nycomed partner Sunovion

07-06-2011

Swiss drugmaker Nycomed, the subject of a $13.7 billion takeover bid from Japan’s Takeda (TYO:4502;…

Ciclesonide Inhalation AerosolNorth AmericaNycomedPharmaceuticalRegulationRespiratory and PulmonarySunovion

Back to top